Adaptive Phage Therapeutics Appoints Robert J. Hopkins, MD, MPH & TM, FACP, FIDSA, to Chief Medical Officer

Adaptive Phage Therapeutics, Inc., (“APT”), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, announced that it has promoted Robert Hopkins, M.D., to Chief Medical Officer. Robert is a highly respected medical and research professional who is a Fellow of the American College of Physicians (FACP) as well as a Fellow of Infectious Disease Society of America (FIDSA). Previously he served as APT’s Vice President of Clinical Development.

Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies to treat multidrug resistant infections. Prior antimicrobial therapeutic approaches have been “fixed,” while pathogens continue to evolve resistance to each of those therapeutics, causing those drug products to become rapidly less effective in commercial use as antimicrobial resistance (AMR) increases over time.